 The FDA has granted Fast Track designation to Antares Pharma Incs NASDAQ: ATRS for ATRS-1902 for adrenal crisis rescue. The development program for ATRS-1902 supports a proposed indication of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using Vai proprietary auto-injector platform to deliver a liquid stable formulation of hydrocortisone. 